Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06510894 · ClinicalTrials.gov registry record
Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression
A clinical trial of Cardiac Sarcoidosis, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT06510894 is a study of Cardiac Sarcoidosis that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 40 participants, below the 90-participant average among 3 other Cardiac Sarcoidosis trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06510894, a study of Cardiac Sarcoidosis, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot mechanistic study of the diagnostic utility of sodium-glucose cotransporter-1/2 inhibition (SGLT1/2) on myocardial glucose suppression on FDG PET/CT. The investigators will test whether the addition of a SGLT1/2 inhibitor (SGLT1/2i) plus the standard dietary modification (ketogenic diet) will provide enhanced myocardial glucose suppression. The primary objective is to assess rates of complete myocardial glucose suppression (MGS) with 7 days of sotagliflozin 400 mg QD among healthy volunteers on a background of 1 day (N=20) or 3 days (N=20) of the KD. The secondary goal is to investigate the relationship between sotagliflozin, targeted metabolite levels, and myocardial glucose utilization on FDG-PET. Participants will be asked to: * undergo a screening visit that includes blood tests, vitals, and questions regarding health history/medications * take the provided sotagliflozin as instructed for 7 days leading up to the scan * follow a ketogenic diet as instructed for 1 or 3 days leading up to the scan * undergo an FDG PET/CT scan, which includes vitals and blood draws
Conditions Studied
Interventions
- DRUG Sotagliflozin
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-11-20 |
| Est. Completion | 2027-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06510894
The ClinicalTrials.gov registry entry for NCT06510894 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 3 other Cardiac Sarcoidosis trials with a reported enrollment target (56% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiac Sarcoidosis appearing as the primary indexed condition, and to 1 intervention - of which Sotagliflozin is the first listed.
NCT06510894 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06510894 about?
NCT06510894 is a clinical study titled "Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression". This is a pilot mechanistic study of the diagnostic utility of sodium-glucose cotransporter-1/2 inhibition (SGLT1/2) on myocardial glucose suppression on FDG PET/CT. The investigators will test whether the addition of a SGLT1/2 inhibitor (SGLT1/2i) plus the standard dietary modification (ketogenic d...
What is the current status of trial NCT06510894?
This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2024-11-20. Estimated completion is 2027-12-31.
What conditions does trial NCT06510894 study?
This clinical trial studies the following conditions: Cardiac Sarcoidosis.
What interventions are being tested in trial NCT06510894?
The interventions under investigation include: Sotagliflozin (DRUG).
Who is sponsoring clinical trial NCT06510894?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06510894 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiac Sarcoidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.